Staphylococcus Aureus Bacteremia
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
BP
Basilea PharmaceuticaSwitzerland - Allschwil
1 program1
Ceftobiprole medocarilPhase 31 trial
Active Trials
Design TherapeuticsCARLSBAD, CA
1 programFollow recommendations based on scientific evidence to S. aureus bacteremia managementN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Basilea PharmaceuticaCeftobiprole medocaril
XBiotech514G3
Design TherapeuticsFollow recommendations based on scientific evidence to S. aureus bacteremia management
Clinical Trials (3)
Total enrollment: 52 patients across 3 trials
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Start: Aug 2018Est. completion: Mar 2022
Phase 3Completed
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
Start: May 2015Est. completion: Dec 201652 patients
Phase 1/2Completed
NCT01971762Design TherapeuticsFollow recommendations based on scientific evidence to S. aureus bacteremia management
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
Start: Apr 2011Est. completion: Jan 2012
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space